Opiant Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Opiant Pharmaceuticals, Inc.
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Biotech regains full rights to a pair of targeted therapies for heart diseases, but will bear full development costs. MyoKardia says the agreement with Sanofi ended due to differences over commercial rights, not concerns about trial data.
While arguing that US FDA overestimated inflation and fill rates when calculating annual cost of co-prescribing naloxone with opioids, Adapt Pharma opened door to pricing pledge questions that the Narcan sponsor could not answer.
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Lightlake Therapeutics Inc.